Related Experiment Videos
A first screening for hemocompatibility of a universal support for selective and specific hemoperfusion
M L Verhoeven1, M Böttcher, F M Everaerts
1Department of Analytical Chemistry, Faculty of Chemical Technology, Eindhoven University of Technology, the Netherlands.
The International Journal of Artificial Organs
|January 1, 1989
Summary
A novel hemoperfusion filmadsorber using activated cellulose nitrate and albumin was developed. Hemocompatibility testing in rabbits demonstrated good performance, indicating potential for selective toxin removal.
Area of Science:
- Biomaterials Science
- Medical Device Engineering
- Hemoperfusion Technology
Background:
- Hemoperfusion requires highly biocompatible materials for selective toxin removal.
- Current hemoperfusion devices face challenges in achieving both specificity and hemocompatibility.
- Development of advanced adsorbents is crucial for improving extracorporeal therapies.
Purpose of the Study:
- To develop and characterize a modified filmadsorber for selective hemoperfusion.
- To evaluate the hemocompatibility of the novel filmadsorber system.
- To establish a platform for coupling various bioactive ligands for targeted toxin adsorption.
Main Methods:
- Fabrication of a spirally wound cellulose nitrate filmadsorber.
- Chemical activation with sodium periodate and albumin immobilization.
- Stabilization and sterilization using glutaraldehyde and dimethylamino borane.
- Hemocompatibility assessment in rabbits, monitoring leukocyte, thrombocyte, and hematocrit levels.
Main Results:
- Successful immobilization of albumin onto activated cellulose nitrate film.
- Stable bonding achieved through glutaraldehyde and dimethylamino borane treatment.
- Hemoperfusion in rabbits showed no adverse effects on leukocyte, thrombocyte, and hematocrit.
- The modified filmadsorber demonstrated good hemocompatibility.
Conclusions:
- The developed filmadsorber exhibits excellent hemocompatibility, suitable for hemoperfusion applications.
- The platform allows for the coupling of diverse bioactive ligands for tailored hemoperfusion therapies.
- This technology holds promise for enhancing the safety and efficacy of extracorporeal blood purification.